<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar depression in adults: Investigational and nonstandard treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar depression in adults: Investigational and nonstandard treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar depression in adults: Investigational and nonstandard treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Gitlin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H231149"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unipolar depression is highly prevalent and disabling. In addition, treatment of unipolar major depression is often unsuccessful. A prospective, observational study initially treated 2876 outpatients with full doses of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> for up to 14 weeks, and found that remission occurred in only 33 percent [<a href="#rid1">1</a>]. With each successive treatment trial, the rate of remission progressively declined [<a href="#rid2">2</a>].</p><p>When depression does respond to treatment, it frequently recurs. Following recovery from one major depressive episode, the estimated rate of recurrence over two years is greater than 40 percent; after two episodes, the risk of recurrence within five years is approximately 75 percent [<a href="#rid3">3</a>].</p><p>As a result, many therapies have been investigated for treatment of depression, but have not been widely adopted, due in part to limited evidence of their efficacy, safety, and tolerability, and the absence of regulatory approval. This topic reviews the evidence for these nonstandard treatments, which may be used in patients not responding to standard treatments for resistant depression.</p><p>The general principles and prognosis for the initial treatment of depression are discussed separately, as are the choice of therapy for the initial treatment of depression and the evidence of efficacy of standard therapies, and the evidence for standard therapies that are used for initially treating depression in primary care patients and in patients with general medical illnesses. Continuation and maintenance treatment of major depression, the treatment of resistant depression, and the clinical manifestations and diagnosis of depression are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90153.html" rel="external">"Unipolar depression in adults and initial treatment: General principles and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90154.html" rel="external">"Unipolar depression in adult primary care patients and general medical illness: Evidence for the efficacy of initial treatments"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91774.html" rel="external">"Unipolar depression in adults: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H84007684"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The treatments for unipolar major depression that are discussed in this topic are typically not used due to limited evidence of their efficacy, safety, and tolerability. For some treatments, the evidence of efficacy is inconsistent, such that some studies indicate the treatment is helpful and other studies do not. Several of the therapies have been investigated in small samples or only one trial and the results need to be replicated before they become standard treatments. In some trials, problematic methods include analyses of study completers (per protocol analysis), which can potentially bias the results, rather than analyzing all patients who were randomized (intent to treat analysis). Another limitation is the lack of longer (eg, &gt;8 weeks) trials to evaluate the benefits and risks; maintenance treatment generally consists of the regimen that achieves remission. In some cases, the treatments lack regulatory approval and are available only through a research protocol.</p><p>For unipolar major depressive episodes that are highly resistant to many treatments, investigational and nonstandard approaches may be warranted, instead of pursuing further trials with standard treatments that may be futile [<a href="#rid4">4</a>]. As an example, investigational treatments may be of interest to patients who do not respond to or tolerate, or who decline, the following standard treatments:</p><p class="bulletIndent1"><span class="glyph">●</span>Antidepressants – Several trials (eg, three to six) with different drugs and classes, including older drugs such as tricyclics or monoamine oxidase inhibitors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjunctive drugs – Multiple trials (eg, two to four) that combine antidepressants with different adjunctive drugs, such as second-generation antipsychotics, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>/<a class="drug drug_general" data-topicid="120589" href="/d/drug information/120589.html" rel="external">esketamine</a>, triiodothyronine, or a second antidepressant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjunctive psychotherapy – At least one trial administered in conjunction with pharmacotherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive transcranial magnetic stimulation – At least one course (eg, 20 to 30 treatments)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electroconvulsive therapy (ECT) – At least one course (eg, 6 to 12 treatments), which includes bilateral electrode placement if patients do not improve initially with right unilateral ECT</p><p></p><p>Investigational and nonstandard treatment includes complementary and alternative therapies, such as dietary supplements and herbal medicines, and practices such as acupuncture, massage, meditation, and yoga [<a href="#rid5">5</a>]. These therapies serve as adjuncts or alternatives to standard (conventional) interventions. Among these therapies are nutraceuticals (nutrient-based products) and phytoceuticals (plant-based products). Treatment that combines standard and complementary therapies is called integrative medicine [<a href="#rid5">5,6</a>]. Additional information about complementary and alternative medicine is available through the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F%2FvRJTX6pAh9HqPuMIdRDLCvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health</a>, which is part of the National Institutes of Health.</p><p>The use of complementary and alternative medicine to treat depression appears to be common [<a href="#rid7">7</a>]. A nationally representative survey in the United States found that among individuals with self-reported depression, approximately 50 percent used a complementary and alternative therapy in the past year [<a href="#rid8">8</a>]. Among individuals treated by a conventional clinician, two-thirds also used a complementary and alternative therapy.</p><p>Prescribed medications and complementary/alternative treatments differ in multiple ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Medications undergo a rigorous process to gain approval by regulatory agencies such as the US Food and Drug Administration and the European Medicines Agency for specific indications. By contrast, nonstandard treatments do not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The quality controls for potency of prescribed medications do not exist for nonstandard treatments, which leads to marked variability in potency across manufacturers of the same nutraceuticals and phytoceuticals. This hampers the utility of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complementary/alternative treatments generally have fewer side effect burdens compared with prescribed medications.</p><p></p><p class="headingAnchor" id="H2537074682"><span class="h1">TREATMENTS THAT MAY BE BENEFICIAL</span></p><p class="headingAnchor" id="H1276219126"><span class="h2">Medications that may be beneficial</span><span class="headingEndMark"> — </span>Investigational and nonstandard medications that may be beneficial are listed below alphabetically.</p><p class="headingAnchor" id="H3146302688"><span class="h3">Botulinum toxin</span><span class="headingEndMark"> — </span>Randomized trials suggest that adjunctive botulinum toxin may benefit patients with unipolar major depression, but loss of blinding due to the drug’s effect upon facial muscles is common [<a href="#rid9">9,10</a>]. A pooled analysis of individual patient data from three randomized trials (total n = 134 patients), each lasting six weeks, compared <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (29 units for females or 40 units for males) with placebo [<a href="#rid11">11</a>]. At baseline, antidepressants were prescribed to 64 percent of the patients; onabotulinumtoxinA and placebo were injected in a single session into the glabellar frown muscles of the forehead. Remission occurred in more patients who received active treatment than placebo (31 versus 7 percent), and adverse events for the two groups were comparable. However, the investigators acknowledged the difficulty of blinding patients and outcome raters.</p><p class="headingAnchor" id="H496006936"><span class="h3">Celecoxib</span><span class="headingEndMark"> — </span>Multiple meta-analyses of randomized trials indicate that <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, an anti-inflammatory drug, can ameliorate depressive syndromes [<a href="#rid12">12-14</a>]. As an example, a meta-analysis of 10 trials, lasting six weeks or one year, compared celecoxib (200 or 400 mg per day) with placebo in 2750 patients with either major depression or depressive symptoms; study drugs were used as monotherapy or add-on therapy (generally with a selective serotonin reuptake inhibitor [SSRI]) [<a href="#rid15">15</a>]. Improvement was greater with celecoxib and the clinical effect was small to moderate; in addition, adverse gastrointestinal or cardiovascular effects were comparable for celecoxib and placebo. However, heterogeneity of the benefit across studies was high, as was risk of bias.</p><p>Some clinicians suggest that anti-inflammatory drugs such as <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> should be reserved for patients with signs of increased inflammation, as indicated by elevated inflammatory biomarkers (eg, C-reactive protein) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/118669.html" rel="external">"Unipolar depression: Neurobiology", section on 'Inflammation'</a>.)</p><p class="headingAnchor" id="H3638584475"><span class="h3">Cytokine inhibitors</span><span class="headingEndMark"> — </span>Cytokine inhibitors are anti-inflammatory drugs that may be useful for depressive syndromes [<a href="#rid17">17</a>]. A meta-analysis of eight randomized trials compared cytokine inhibitors with placebo for 12 or 52 weeks in patients with depressive symptoms (n &gt;3300) [<a href="#rid14">14</a>]. Active treatments included <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">ixekizumab</a>, or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>; nearly all patients had somatic comorbidity, such as psoriasis or rheumatoid arthritis, and received study treatments as monotherapy. Improvement of depression was superior with cytokine inhibitors and the clinical effect was moderate. However, heterogeneity across studies was large, and the analysis did not clarify whether improvement of depression was independent of improvement in somatic morbidity.</p><p class="headingAnchor" id="H1937630566"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are anti-inflammatory drugs that may temporarily help treatment-resistant depression [<a href="#rid17">17</a>]. A meta-analysis of two trials compared corticosteroids (corticotropin-releasing hormone, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, or <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>) as add-on treatment for two or four days in 59 patients with unipolar major depression [<a href="#rid14">14</a>]. Improvement was superior with glucocorticoids and the clinical effect was large. However, long-term use of glucocorticoids is associated with serious potential side effects and toxicities and should generally be avoided.</p><p class="headingAnchor" id="H3550782900"><span class="h3">Minocycline</span><span class="headingEndMark"> — </span>For patients with treatment-resistant depression, multiple randomized trials indicate that the antibiotic <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> may be beneficial and well tolerated [<a href="#rid17">17,18</a>]. Two separate meta-analyses of the same three trials compared minocycline (200 mg/day) with placebo, either as add-on therapy or monotherapy, in 151 patients with depressive syndromes [<a href="#rid14">14,19</a>]. Improvement was greater with active drug and the clinical effect was large; in addition, adverse effects were comparable for the two groups. However, heterogeneity of the benefit across studies was moderate to large.</p><p>Some clinicians have emphasized that anti-inflammatory drugs such as <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> should be reserved for patients with signs of increased inflammation, as indicated by elevated inflammatory biomarkers such as C-reactive protein [<a href="#rid16">16</a>]. Limited evidence supporting this approach includes a four-week randomized trial that compared add-on minocycline (200 mg/day) with placebo in 39 patients with treatment-resistant depression plus low-grade inflammation, defined as C-reactive protein serum concentration ≥1 mg/L. Although the benefit of minocycline and placebo was comparable, among patients with C-reactive protein ≥3 mg/L, improvement was greater with minocycline.</p><p>Additional information about inflammation in unipolar depression is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/118669.html" rel="external">"Unipolar depression: Neurobiology", section on 'Inflammation'</a>.)</p><p class="headingAnchor" id="H84007329"><span class="h3">Scopolamine</span><span class="headingEndMark"> — </span>Studies of intravenous <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> monotherapy suggest that the drug has antidepressant effects, and that augmentation with scopolamine may also be helpful [<a href="#rid20">20,21</a>]. As an example, a six-week randomized trial compared oral scopolamine (0.5 mg per twice per day) with placebo in 40 patients with major depression who were treated with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (40 mg per day) [<a href="#rid22">22</a>]. Exclusion criteria included cognitive impairment, narrow-angle glaucoma, and prostatic hypertrophy; all patients received an eye examination and all males age &gt;40 years underwent a digital rectal examination prior to enrollment. Remission occurred in more patients treated with scopolamine than placebo (65 versus 20 percent). However, scopolamine caused higher rates of blurred vision, dizziness, and dry mouth.</p><p class="headingAnchor" id="H17746219"><span class="h3">Statins</span><span class="headingEndMark"> — </span>Combining statins with antidepressants may be efficacious for treating unipolar major depression [<a href="#rid23">23</a>]. Two separate meta-analyses of the same three randomized trials lasting 6 to 12 weeks compared statins with placebo in 165 patients treated with SSRIs [<a href="#rid24">24,25</a>]. Improvement was greater with statins than placebo, and the clinical effect was moderate to large. In addition, the safety profile of statins and placebo was comparable. Another meta-analysis included seven trials, lasting six weeks to four years, in 1576 patients; improvement of depression was greater with statins than placebo, and the effect was small to moderate [<a href="#rid14">14</a>].</p><p>Information about the administration and potential adverse effects of statins is discussed separately. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration"</a>.)</p><p class="headingAnchor" id="H4189307441"><span class="h3">Zuranolone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="142248" href="/d/drug information/142248.html" rel="external">Zuranolone</a> can be efficacious for depression and appears to have a relatively rapid onset of action. Two randomized trials, each lasting two weeks, both found that zuranolone was beneficial in patients with unipolar major depression (n = 89 and 534) [<a href="#rid26">26,27</a>]. As an example, the larger trial compared zuranolone (50 mg/day) with placebo as monotherapy or add-on treatment; greater improvement of depression occurred with zuranolone by day 3, and the clinical advantage of zuranolone throughout treatment was small to moderate [<a href="#rid27">27</a>]. Adverse effects that occurred in at least 5 percent of the patients treated with zuranolone and twice as often with zuranolone than placebo included dizziness and somnolence.</p><p>Other randomized trials have found that <a class="drug drug_general" data-topicid="142248" href="/d/drug information/142248.html" rel="external">zuranolone</a> can help patients with postpartum depression. (See  <a class="medical medical_review" href="/d/html/88582.html" rel="external">"Severe postpartum unipolar major depression: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H1210461990"><span class="h2">Complementary and alternative treatments that may be beneficial</span></p><p class="headingAnchor" id="H690501610"><span class="h3">Bright light therapy</span><span class="headingEndMark"> — </span>Using bright light therapy, also called phototherapy, to treat nonseasonal unipolar major depression is consistent with multiple practice guidelines [<a href="#rid28">28-32</a>]. In addition, the intervention is a standard, widely used treatment for mild to moderate unipolar major depression with a seasonal pattern.</p><p>Based upon randomized trials, the general principles for using bright light therapy in nonseasonal unipolar major depression include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients – Treatment is efficacious for mild to moderate depression (eg, no suicidal behavior), but not severe depression [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Format – Bright light therapy can be administered as monotherapy [<a href="#rid33">33-35</a>], or in combination with pharmacotherapy, such as an SSRI [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose – Prescribe a dose of 5000 to 10,000 lux for 30 to 60 minutes/day in the morning rather than other times of day [<a href="#rid33">33,34,36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration – The minimum necessary length of treatment appears to be two weeks [<a href="#rid34">34</a>], and some trials have lasted five or eight weeks [<a href="#rid33">33,34,36,37</a>].</p><p></p><p>Evidence supporting the use of bright light therapy for nonseasonal depression includes several meta-analyses of randomized trials [<a href="#rid34">34-38</a>]. As an example, a meta-analysis of 13 trials compared bright light therapy with control conditions (eg, red or dim light) in 565 patients [<a href="#rid33">33</a>]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received active treatment than controls (59 versus 38 percent).</p><p>Additional information about bright light therapy, including administration, safety, and side effects, is discussed separately in the context of seasonal affective disorder. (See  <a class="medical medical_review" href="/d/html/101250.html" rel="external">"Seasonal affective disorder: Treatment", section on 'Bright light therapy'</a>.)</p><p class="headingAnchor" id="H966404443"><span class="h3">Carnitine supplements</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">Carnitine supplements</a> are dietary supplements that are derived from amino acids and may be useful for treatment of unipolar depression. A meta-analysis of nine randomized trials compared carnitine supplements with placebo in 467 patients with depressive syndromes that were the primary indication or a secondary indication in patients with fibromyalgia, migraine, or minimal hepatic encephalopathy [<a href="#rid39">39</a>]. Carnitine supplements (most often 3 g/day) and placebo were prescribed as monotherapy in the large majority of patients, and or as add-on treatment with an antidepressant. The median length of treatment was eight weeks. Improvement of depression was greater with carnitine supplements than placebo and the clinical effect was large. In addition, the risk of adverse effects in the two groups was comparable. However, inconsistency across studies was large and there was evidence of publication bias.</p><p>Additional information about <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">carnitine supplements</a> is available from the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2Ffactsheets%2FCarnitine-HealthProfessional%2F&amp;token=VWBorz9XipJYgCS51pWoNkffQbIBvvJjZOpil31HjcvdGQcIQJhNHLrFDpbUbog3I07esxnM5CYcFNY%2F%2FdfkhnhfWFeF%2Fz7Qoqj9nnGoVJU%3D&amp;TOPIC_ID=90155" target="_blank">National Institutes of Health: Office of Dietary Supplements</a>.</p><p class="headingAnchor" id="H1393467989"><span class="h3">Chronotherapy</span><span class="headingEndMark"> — </span>Chronotherapy combines at least two of the following: sleep deprivation, bright light therapy, and sleep phase advance. Sleep deprivation involves depriving patients their normal sleep, either for the entire night or the second half of the night. Sleep phase advance involves going to bed and waking up earlier than usual. Each component of chronotherapy is administered for different lengths of time. It is hypothesized that chronotherapy resets and stabilizes circadian rhythms by synchronizing internal circadian rhythms to the environmental light/dark cycle [<a href="#rid40">40</a>].</p><p>Based upon randomized trials, chronotherapy may perhaps be a useful adjunct for short-term treatment of depression. A meta-analysis of four trials compared chronotherapy (sleep deprivation plus bright light therapy) with control conditions (exercise, dim light, or usual care) in 202 patients with depressive syndromes treated with pharmacotherapy [<a href="#rid40">40</a>]. Improvement of depression on day 5 to 7 was greater with chronotherapy than control conditions, and the clinical effect was moderate to large. However, it’s not clear whether sleep deprivation provided any additional benefit to bright light therapy, which appears to be beneficial as monotherapy. (See <a class="local">'Bright light therapy'</a> above.)</p><p>If sleep deprivation is used as a monotherapy for depression, its benefits are transient, such that increased depressive symptoms typically recur after a full night of sleep.</p><p class="headingAnchor" id="H2468145100"><span class="h3">Creatine</span><span class="headingEndMark"> — </span>Combining creatine with an antidepressant may be useful in the short-term treatment of depression. An eight-week randomized trial compared creatine monohydrate (5 g per day) plus <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (10 to 20 mg per day) with placebo plus escitalopram in 52 women with unipolar major depression [<a href="#rid41">41</a>]. Exclusion criteria included comorbid renal disease and serum creatinine levels that exceeded the normal range (&gt;1.1 mg/dL). Remission occurred in more patients who received creatine than placebo (52 versus 26 percent). Adverse events were comparable for the two groups, and serum creatinine and blood urea nitrogen levels were within normal limits during the trial.</p><p>Additional information about creatine is available from the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2Ffactsheets%2FExerciseAndAthleticPerformance-Consumer%2F&amp;token=u10DUvCim43ZNk%2FxF%2B3O0VpAV7E1UKtq86ZaiuWYD5%2FbbQlUZgjxUqVZ5JRsHl5a6uSkCMY96QGrkk35ebIKfY%2BPZyEJ5BlotHoZKBPLYDw%3D&amp;TOPIC_ID=90155" target="_blank">National Institutes of Health: Office of Dietary Supplements</a>.</p><p class="headingAnchor" id="H1341282092"><span class="h3">Folate derivatives</span><span class="headingEndMark"> — </span>Although the evidence suggests that the folate derivatives <a class="drug drug_general" data-topicid="10342" href="/d/drug information/10342.html" rel="external">methylfolate</a> and S-adenosyl methionine (SAMe) may perhaps be beneficial for unipolar depression, multiple randomized trials indicate that folate (<a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>) is not. (See <a class="local">'Complementary and alternative treatments'</a> below.)</p><p class="headingAnchor" id="H238682356"><span class="h4">Methylfolate</span><span class="headingEndMark"> — </span>Adjunctive <a class="drug drug_general" data-topicid="10342" href="/d/drug information/10342.html" rel="external">methylfolate</a>, which is the form of folate that crosses the blood brain barrier, may be effective for treatment-resistant depression [<a href="#rid42">42</a>]. A meta-analysis of two small randomized trials compared methylfolate (15 mg/day) with placebo as add-on treatment in 99 patients with unipolar major depression that had not responded to an antidepressant (eg, SSRI) [<a href="#rid43">43</a>]. Improvement was greater with active drug and the clinical effect was moderate to large. Use of methylfolate for depression is consistent with multiple practice guidelines [<a href="#rid5">5,29,44</a>].</p><p class="headingAnchor" id="H3621704625"><span class="h4">S-adenosyl methionine</span><span class="headingEndMark"> — </span>SAMe is a metabolite of folate that facilitates the synthesis of neurotransmitters (including dopamine, norepinephrine, and serotonin) and is available over-the-counter as a dietary supplement in the United States [<a href="#rid45">45</a>]. It is not clear whether SAMe is beneficial for unipolar major depression, due to the lack of high-quality evidence supporting its use [<a href="#rid45">45</a>]. Nevertheless, multiple practice guidelines recommended SAMe as adjunctive treatment for unipolar depression [<a href="#rid5">5,29,44</a>].</p><p>Evidence supporting the use of SAMe includes a six-week randomized trial that compared add-on SAMe (800 mg twice per day) with placebo in 73 patients with unipolar major depression who failed treatment with an SSRI or serotonin-norepinephrine reuptake inhibitor; remission occurred in more patients who received SAMe (26 versus 12 percent) [<a href="#rid46">46</a>]. In addition, discontinuation of treatment due to adverse effects was numerically less with SAMe than placebo (5 versus 9 percent).</p><p class="bulletIndent2">However, other randomized trials that evaluated SAMe for depression have yielded results that are difficult to interpret due to methodologic problems. As an example:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 12-week randomized trial in 189 patients found that response to SAMe (1600 to 3200 mg/day), <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (10 to 20 mg/day), or placebo was comparable [<a href="#rid47">47</a>]. These results rendered the study a failed trial, given that escitalopram is a well-established antidepressant based upon its efficacy in multiple trials [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of four randomized trials (n = 619 depressed patients) found that improvement was comparable with either SAMe or <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a>; however, the trials lacked a placebo arm to calibrate the results [<a href="#rid45">45</a>].</p><p></p><p>General information about SAMe is available from the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2Ffactsheets%2Flist-all%2F&amp;token=2%2BVUdM5u3ipFY2ffOQIu0kMVD4ImnhO2hKDhIhHICErJrFhfomgkzUsiaeUnhAfshje17gNeaal5AanyMbSRkA%3D%3D&amp;TOPIC_ID=90155" target="_blank">National Institutes of Health Office of Dietary Supplements</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Fsadenosyllmethionine-same-in-depth&amp;token=ubeIQVcBfEroU%2Bpqx1hV5E5WRK3KZI%2F0QE7Tjy%2FFpeQCEgx%2BMlks5tstYB6vZwnP3hYHeeo%2FU%2BXqWpX7B2kt9IdrtuN%2B626Xau6xIyia9K8%3D&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health</a>.</p><p class="headingAnchor" id="H2198110662"><span class="h3">Glycyrrhizic acid</span><span class="headingEndMark"> — </span>Glycyrrhizic acid is an herbal extract that may accelerate response to initial treatment of depression. A four-week randomized trial compared glycyrrhizic acid (150 mg three times daily) plus <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (5 to 20 mg/day) with placebo plus escitalopram in patients with unipolar major depression (n = 56) [<a href="#rid49">49</a>]. Response occurred in more patients who received adjunctive glycyrrhizic acid than placebo (67 versus 38 percent). In addition, the rate of adverse events in the two groups was comparable.</p><p class="headingAnchor" id="H1405958004"><span class="h3">Meditation</span><span class="headingEndMark"> — </span>Meditation may be beneficial as add-on treatment for treatment-resistant depression [<a href="#rid50">50</a>]. An eight-week, open-label randomized trial compared adjunctive meditation with a wait list control condition in patients (n = 25) with unipolar major depression that did not respond to at least eight weeks of antidepressant treatment [<a href="#rid51">51</a>]. The meditation intervention was a group program that included breathing exercises, yoga postures, and sitting meditation; the program required 3.5 hours/day for the first week and 2 hours/day for the remaining seven weeks. Adjunctive meditation led to greater improvement of depression and was well tolerated.</p><p>Meditation is a component of mindfulness-based cognitive therapy, which is a standard treatment that combines the clinical application of mindfulness meditation with elements of cognitive-behavioral therapy. (See  <a class="medical medical_review" href="/d/html/14682.html" rel="external">"Unipolar major depression: Treatment with mindfulness-based cognitive therapy"</a>.)</p><p class="headingAnchor" id="H3980859508"><span class="h3">Music therapy</span><span class="headingEndMark"> — </span>Music therapy includes regular meetings with a therapist who uses music to help patients process and express their experiences and feelings [<a href="#rid52">52</a>]. The intervention can be administered in an individual or group format, and consists of active methods (compositional, improvisational, or recreative) in which patients make music, and receptive methods in which patients listen to music.</p><p>The evidence that suggests adjunctive music therapy may be helpful includes a meta-analysis of three open-label randomized trials and one prospective controlled observational study that compared music therapy plus usual care (eg, antidepressants and psychotherapy) with usual care alone in a total of 219 patients with unipolar depression [<a href="#rid52">52</a>]. Music therapy included 12 to 48 sessions administered over six weeks to three months. Improvement was greater in patients who received music therapy, and the clinical benefit was large.</p><p class="headingAnchor" id="H165221969"><span class="h3">N-acetylcysteine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> is derived from the amino acid cysteine, is available over-the-counter, and may possibly be useful for treatment-resistant depression [<a href="#rid53">53</a>]. A 12-week randomized trial compared N-acetylcysteine (1000 mg twice daily) with placebo as add-on treatment in 252 patients with unipolar major depression [<a href="#rid54">54</a>]. Improvement at week 12 was comparable for the two groups, but follow-up assessments at week 16 found that response occurred in more patients who received add-on N-acetylcysteine than placebo (37 versus 25 percent). Adverse gastrointestinal and musculoskeletal complaints were greater with N-acetylcysteine.</p><p class="headingAnchor" id="H1759257037"><span class="h3">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>Omega-3 fatty acids (n-3 polyunsaturated fatty acids), which are found in high concentrations in some “oily” species of fish, may be helpful as add-on therapy for unipolar major depression [<a href="#rid55">55,56</a>]. For patients treated with omega-3 fatty acids, we suggest prescribing either of the most widely studied formulations [<a href="#rid5">5,30,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pure eicosapentaenoic acid 1 to 2 g/day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eicosapentaenoic acid 1 to 2 g/day plus docosahexaenoic acid, in a ratio greater than 2:1</p><p></p><p>The starting dose of eicosapentaenoic acid is 1 g/day [<a href="#rid56">56</a>]. For patients who tolerate the medication but do not respond satisfactorily for after two to four weeks, the dose is increased to 2 g/day. An adequate acute treatment trial lasts at least eight weeks; randomized trials have lasted up to 16 weeks.</p><p>Omega-3 fatty acids are generally well tolerated and carry little risk of serious adverse effects [<a href="#rid30">30,56</a>]. The most common mild side effects include belching, fishy aftertaste, nausea, pruritus, and skin eruptions. However, patients receiving omega-3 fatty acid-containing products (or substantially increasing the content of omega-3 fatty acids in their diets) in conjunction with an anticoagulant should be monitored for signs and symptoms of bleeding or excessive bruising [<a href="#rid5">5,30</a>]. Specific interactions of omega-3 fatty acids with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>Evidence supporting augmentation of antidepressants with omega-3 fatty acids (especially eicosapentaenoic acid) for unipolar depression includes multiple meta-analyses of randomized trials [<a href="#rid30">30,53,56,57</a>]. Across different meta-analyses, the primary findings include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement is greater with omega-3 fatty acids than placebo, and the clinical benefit is generally moderate [<a href="#rid58">58-61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Omega-3 fatty acids are efficacious when combined with antidepressants, but not as monotherapy [<a href="#rid58">58,60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formulations of pure or mainly eicosapentaenoic acid are efficacious, whereas formulations of pure or mainly docosahexaenoic acid are not [<a href="#rid58">58,60,61</a>]. In addition, there is a dose-response relationship with eicosapentaenoic acid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline severity of depression is not associated with efficacy [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefit of omega-3 fatty acids may be limited to patients without general medical comorbidity (eg, coronary heart disease, diabetes, or neurologic disease) [<a href="#rid59">59</a>].</p><p></p><p>The potential value and relative safety of omega-3 fatty acids for treating depressive syndromes is underscored by their inclusion in multiple practice guidelines [<a href="#rid5">5,28,29,56</a>].</p><p>The United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Fomega3-supplements-in-depth&amp;token=MKDjnhu7z5Zjm1BZiP4FsxtrmsUW5ZLFSmDePfHPx7Eu%2BfT6sY5Unc9AQ07V11mxrqGD%2FZiZiNIo0h8YNSldHarQqOdo%2BLC9sZESPPydEAM%3D&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmedlineplus.gov%2Fdruginfo%2Fmeds%2Fa607065.html&amp;token=d5ngiCbB8xFYJWkFI1xcekh7CTTcVcbY3fVxLXEvc7Q2W80JnGxANdanLomfycvPBrJ9cr9cDRv0xC%2FjpSnCew%3D%3D&amp;TOPIC_ID=90155" target="_blank">National Library of Medicine</a> discuss the use of omega-fatty acids, including its use for depression.</p><p>Information about the benefits, adverse effects, and safety of omega-3 fatty acids for cardiovascular health is discussed separately. (See  <a class="medical medical_review" href="/d/html/5365.html" rel="external">"Fish oil: Physiologic effects and administration"</a>.)</p><p class="headingAnchor" id="H1024365400"><span class="h3">Probiotics</span><span class="headingEndMark"> — </span>Probiotics are live microorganisms such as bacteria and yeast, and multiple small studies suggest that adjunctive probiotics are potentially efficacious for treating depression. A meta-analysis of five, low-quality randomized trials compared add-on probiotics with placebo in 254 depressed patients treated with an antidepressant (usually an SSRI); improvement was greater with probiotics and the clinical benefit was large [<a href="#rid62">62</a>]. In addition, a subsequent eight week trial in 49 patients with treatment-resistant depression found that improvement was greater with an add-on multistrain probiotic than placebo on one outcome measure, but comparable on another [<a href="#rid63">63</a>]. Side effects in the probiotic group were mild.</p><p>Additional information about probiotics is available at the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F%2FvRJTX6pAh9HqPuMIdRDLCvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2F&amp;token=2%2BVUdM5u3ipFY2ffOQIu0vX60lz4f72cTEfZp1JirQo%3D&amp;TOPIC_ID=90155" target="_blank">National Institutes of Health: Office of Dietary Supplements</a>.</p><p class="headingAnchor" id="H484288264"><span class="h3">St. John's wort</span><span class="headingEndMark"> — </span>For patients who present with unipolar major depression, St. John’s wort (extracts of the plant <em>Hypericum perforatum</em>) appears to be helpful. Nevertheless, we suggest that clinicians <strong>not</strong> prescribe it. Preparations of the drug vary in potency and are not standardized, the proper dose of St. John’s wort is not clear, it is not known if the drug is appropriate for patients with severe depression, and the active component is not known [<a href="#rid64">64-67</a>]. St. John’s wort preparations are often of poor quality or adulterated with other <em>Hypericum</em> species and food dyes. In addition, the maximum duration of treatment in randomized trials is 12 weeks and the persistence of the drug’s effects are thus not known. Avoiding St. John’s wort for the initial treatment of major depression is consistent with practice guidelines from the American Psychiatric Association, Royal Australian and New Zealand College of Psychiatrists, and the United Kingdom National Institute of Health and Clinical Excellence [<a href="#rid28">28,64-66</a>]. Nevertheless, other treatment guidelines endorse St. John’s wort [<a href="#rid5">5,29,68</a>].</p><p>Randomized trials indicate that St. John’s wort can be efficacious and is relatively well tolerated [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of randomized trials concluded that the efficacy of St. John’s wort was superior to placebo and comparable to standard antidepressants, and that tolerability was superior with St. John’s wort compared with standard antidepressants; however, interpretation of the results is difficult because country of origin was associated with the benefits of St. John’s wort [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 27 randomized trials compared St. John’s wort with SSRIs in patients diagnosed with depressive syndromes (n = 3126), and found that improvement, response, and remission were each comparable for the two groups, whereas adverse effects were less likely to occur with St. John’s wort (relative risk 0.77, 95% CI 0.70-0.84) [<a href="#rid70">70</a>]. A subsequent meta-analysis (27 trials, 3808 patients) found similar results [<a href="#rid71">71</a>].</p><p></p><p>St. John’s wort can potentially cause serious drug-drug interactions [<a href="#rid72">72</a>]. As an example, St. John’s wort appears to induce metabolism of other drugs (eg, anticoagulants, anticonvulsants, antiretrovirals, immunosuppressants, and hormonal contraceptives) via CYP3A4 hepatic enzymes. Also, concurrent use of St. John’s wort with SSRIs can cause the serotonin syndrome [<a href="#rid28">28,42</a>]. Specific interactions of St. John’s wort with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>Additional information about St. John’s Wort is discussed separately. (See  <a class="medical medical_review" href="/d/html/1391.html" rel="external">"Clinical use of St. John's wort"</a>.)</p><p>The United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Fst-johns-wort&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fz3wh0Bqb8lzeSfvlLTqiX7TEieJfgwTcOp5FWgweNFyUGHi0UhbZlJMTCOpTFXlHw%3D%3D&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health website</a>, which is part of the National Institute of Health, also discusses St. John’s Wort, including its use for depression.</p><p class="headingAnchor" id="H1860858696"><span class="h3">Whole body hyperthermia</span><span class="headingEndMark"> — </span>Multiple randomized trials suggest that whole body heating may possibly ameliorate depression [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial compared a single session of whole body hyperthermia with a sham condition in 29 patients with unipolar major depression who were subsequently followed for up to six weeks [<a href="#rid74">74</a>]. Neither antidepressants nor psychotherapy were allowed during the trial, and all patients were otherwise medically healthy. Whole body hyperthermia was induced with infrared lights and heating coils that raised the core body temperature to 38.5°C (101.3°F); the mean length of time required to do so was 107 minutes. Improvement was greater with whole body hyperthermia than the sham condition within one week and the benefit of active treatment persisted for six weeks. Adverse effects for the two groups were comparable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label, eight-week randomized trial, 36 patients with unipolar depressive syndromes were randomly assigned to hyperthermic baths or a sham control condition two times per week for two weeks [<a href="#rid75">75</a>]. Patients receiving antidepressants at baseline continued pharmacotherapy during the trial. During treatment with hyperthermic baths, patients immersed their entire bodies, except the head, in a 40°C (104°F) pool for 20 to 30 minutes. Patients were then wrapped in warm blankets with hot water bottles filled with boiling water for at least 30 minutes. The control condition consisted of exposure to green light (&lt;400 lux) for less than 40 minutes. At week 2, after four interventions, improvement of depression was greater with active treatment. However, at week 8, improvement was comparable in the two groups.</p><p></p><p class="headingAnchor" id="H3155166929"><span class="h1">TREATMENTS THAT DO NOT APPEAR TO BE BENEFICIAL</span></p><p class="headingAnchor" id="H826249070"><span class="h2">Medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buprenorphine</strong><strong> plus samidorphan</strong> – <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> and samidorphan each act upon opioid receptors. A meta-analysis of five trials typically lasting four to six weeks compared add-on buprenorphine plus samidorphan with placebo in patients who did not respond to an antidepressant (n &gt;1200); the combination provided no advantage over placebo [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-</strong><strong>cycloserine</strong> – A small, six-week randomized trial in 26 patients with unipolar major depression resistant to antidepressants found that improvement was greater with add-on D-cycloserine (1000 mg/day) than placebo [<a href="#rid77">77</a>]. However, a previous trial by the same investigators in 22 treatment-resistant patients found that a smaller dose of adjunctive D-cycloserine (250 mg/day) was not beneficial [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Memantine</strong> – A meta-analysis of three randomized trials in 92 patients with unipolar or bipolar depression found that the likelihood of response with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> (generally 20 mg/day) or placebo, either as monotherapy or augmentation, was comparable [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metyrapone</strong> – The antiglucocorticoid <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> does not appear to help patients with treatment-resistant depression, based upon a five-week randomized trial in 143 patients treated with add-on metyrapone (500 mg twice daily) or placebo [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrous oxide</strong> – <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> is a clinically available N-methyl-D-aspartate (NMDA) receptor antagonist akin to <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> and is a standard anesthetic drug that has been studied in patients with treatment-resistant depression. A randomized trial compared adjunctive inspiratory nitrous oxide (50 percent nitrous oxide plus 50 percent oxygen) with placebo (50 percent nitrogen plus 50 percent oxygen) in patients with treatment-resistant depression who were receiving a stable treatment regimen (n = 20) [<a href="#rid81">81</a>]. Study drugs were administered in a single session lasting one hour. Improvement of depression was greater with add-on nitrous oxide than placebo at 2 hours, 24 hours, and one-week posttreatment. However, longer term benefits and toxicity of nitrous oxide are unknown. In addition, nitrous oxide may be abused because of its intoxicating properties.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pindolol</strong> – Although the combination of <a class="drug drug_general" data-topicid="9774" href="/d/drug information/9774.html" rel="external">pindolol</a> plus an antidepressant has demonstrated efficacy as initial treatment for major depression, the benefits appear to wane or disappear. Two separate meta-analyses of randomized trials compared pindolol with placebo in patients with unipolar major depression who were treated with selective serotonin reuptake inhibitors (SSRIs; total n = 889 patients) [<a href="#rid82">82,83</a>]. Both meta-analyses found that within two weeks, response (reduction of baseline symptoms ≥50 percent) was substantially more likely with adjunctive pindolol than placebo. However, within six weeks, the advantage of pindolol in one meta-analysis was marginal [<a href="#rid82">82</a>] and in the other study had disappeared [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pioglitazone</strong> – A meta-analysis of two randomized trials in 77 patients with unipolar major depression found that the benefit of antidepressants plus add-on treatment with <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> or placebo was comparable [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Riluzole</strong><strong> </strong>– An eight-week randomized trial in 104 patients with treatment-resistant depression found that improvement with antidepressants plus adjunctive <a class="drug drug_general" data-topicid="9865" href="/d/drug information/9865.html" rel="external">riluzole</a> (50 mg twice daily) or placebo was comparable [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testosterone</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Males</strong> – For depressed men who do not have hypogonadism, it appears that exogenous <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> is not beneficial [<a href="#rid85">85</a>]. A meta-analysis of two randomized trials (n = 103 depressed, eugonadal men) compared intramuscular testosterone with placebo and found that active treatment was not beneficial [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2">In a subsequent meta-analysis of 27 randomized trials that compared <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> with placebo in 1890 males with depression, improvement was greater with testosterone [<a href="#rid87">87</a>]. Nevertheless, some experts concluded that the results did not support using testosterone to treat unipolar depression, based upon the following methodologic problems [<a href="#rid85">85</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Many of the patients entered the trials without depressive disorders such as unipolar major depression or persistent depressive disorder (dysthymia). In addition, the heterogenous patient population included males with a variety of general medical conditions, including hypogonadism.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Risk of bias in the underlying trials was high or not clear.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The clinical benefit of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in the meta-analysis was small and may not have been clinically meaningful.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The long-term safety of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> is unknown.</p><p></p><p class="bulletIndent2">In males with hypogonadism, it is not known whether <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> improves unipolar major depression [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Other possible effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Females</strong> – <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> does not appear to be beneficial for females with treatment-resistant depression. An eight-week randomized trial compared add-on, low-dose testosterone cream (mean 12 mg/day) with placebo in female patients with treatment-resistant unipolar major depression (n = 101); response was nearly the same in both groups (approximately 48 percent) [<a href="#rid88">88</a>].</p><p></p><p class="headingAnchor" id="H413823645"><span class="h2">Complementary and alternative treatments</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabis</strong> – For treatment-refractory depression, we suggest that patients avoid using plant-based and pharmaceutical cannabinoids due to the lack of any apparent benefit and the potential for adverse effects and harms.</p><p></p><p class="bulletIndent1">Evidence indicating that cannabis is not helpful for depression includes a systematic review and meta-analysis of 12 randomized trials that compared adjuvant cannabinoids with placebo in 1656 patients with depressive syndromes [<a href="#rid89">89</a>]. The primary indication in each trial was a general medical disorder, such as chronic noncancer pain or multiple sclerosis, with depression as a secondary indication. Active treatment in nearly all trials consisted of pharmaceutical grade delta-9-tetrahydrocannabinol (THC) in the form of <a class="drug drug_general" data-topicid="9394" href="/d/drug information/9394.html" rel="external">dronabinol</a>, <a class="drug drug_general" data-topicid="9995" href="/d/drug information/9995.html" rel="external">nabilone</a>, or <a class="drug drug_general" data-topicid="9457" href="/d/drug information/9457.html" rel="external">nabiximols</a>. During treatment that generally lasted 4 to 12 weeks, improvement of depression was comparable with cannabinoids and placebo.</p><p></p><p class="bulletIndent1">The same review also examined the adverse effects of adjunctive cannabinoids in patients with symptoms of depression, anxiety, attention deficit hyperactivity disorder, or posttraumatic stress disorder [<a href="#rid89">89</a>]. A meta-analysis of 10 trials (n = 1495 patients) found that adverse events were two times more likely to occur with cannabinoids than placebo (odds ratio 2.0, 95% CI 1.2-3.3). In addition, a meta-analysis of 11 trials (n = 1621 patients) showed that discontinuation of treatment due to adverse events was nearly three times more likely with add-on cannabinoids (odds ratio 2.8, 95% CI 1.6-4.9).</p><p></p><p class="bulletIndent1">The risk of harm from using cannabis in patients with depression led The National Academies of Sciences, Engineering, and Medicine to issue a report in 2017, which concluded that cannabis use is associated with an increased incidence of suicide attempts and deaths [<a href="#rid90">90</a>]. The following year, the American Psychiatric Association formally opposed the use of cannabis as medicine, due in part to the risks of cannabis in patients with unipolar major depression, including increased rates of suicide attempts [<a href="#rid91">91</a>]. A 2022 practice guideline from the Canadian Network for Mood and Anxiety Treatments recommends not using cannabis to treat depression because it is associated with a worse course of illness and poorer functioning, including increased suicidal ideation [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Additional information about the adverse consequences of cannabis use are discussed in separately. (See  <a class="medical medical_review" href="/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Folate</strong> – Two meta-analyses of randomized trials (n = 657 and 671) indicate that add-on folate (<a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>), at a dose of (0.5 to 10 mg per day), is not useful for treatment-resistant depression [<a href="#rid43">43,57</a>]. In addition, other studies of folate have raised safety concerns, including masked B12 deficiency [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Additional information about folate is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2Ffactsheets%2Flist-all%2F&amp;token=2%2BVUdM5u3ipFY2ffOQIu0kMVD4ImnhO2hKDhIhHICErJrFhfomgkzUsiaeUnhAfshje17gNeaal5AanyMbSRkA%3D%3D&amp;TOPIC_ID=90155" target="_blank">United States National Institutes of Health: Office of Dietary Supplements</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmedlineplus.gov%2Fdruginfo%2Fnatural%2F1017.html&amp;token=d5ngiCbB8xFYJWkFI1xcekh7CTTcVcbY3fVxLXEvc7QJsfuFxf5hVrH1JvImW%2F27NEC5JIWYblk9EceU2%2BCHtg%3D%3D&amp;TOPIC_ID=90155" target="_blank">MedlinePlus</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inositol</strong> – A meta-analysis of two randomized trials lasting four weeks in 78 patients receiving SSRIs for unipolar major depression found that the benefits of add-on inositol (12 mg/day) and placebo was comparable [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium</strong> – In a meta-analysis of eight randomized trials in 538 patients with depressive syndromes who were treated for 1 to 12 weeks with magnesium (225 to 4000 mg/day) or placebo, improvement was comparable [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhodiola</strong> – Evidence regarding the efficacy of the herb <em>Rhodiola rosea</em> in depressed patients is mixed. In a 12-week trial that evaluated adjunctive Rhodiola, 98 patients with mild to moderate unipolar major depression were each treated with <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> (dose not specified) and randomly assigned to adjunctive Rhodiola 0.3 g/day, Rhodiola 0.6 g/day, or placebo [<a href="#rid96">96</a>]. Improvement of depression was greater with each dose of adjunctive Rhodiola than placebo, and Rhodiola was well tolerated.</p><p></p><p class="bulletIndent1">In two monotherapy trials that compared Rhodiola with placebo for depression, the results were inconsistent. A six-week trial in 89 patients found that Rhodiola 340 mg/day and Rhodiola 680 mg/day were each more efficacious than placebo [<a href="#rid97">97</a>]. By contrast, a 12-week trial in 38 patients found that improvement with Rhodiola 340 mg/day and placebo was comparable [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1">General information about Rhodiola is available from the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Frhodiola&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fz3wh0Bqb8lzeSfvlLTqiX4TFHQ6n2mnpDhRczH3TxOp&amp;TOPIC_ID=90155" target="_blank">National Center for Complementary and Integrative Health</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcosine</strong> – Sarcosine (also known as N-methylglycine) is derived from the amino acid glycine [<a href="#rid99">99</a>]. A six-week randomized trial compared sarcosine (mean dose 900 mg per day) with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (mean dose 27 mg per day) in 40 patients with unipolar major depression [<a href="#rid100">100</a>]. Remission occurred in more patients who received sarcosine than citalopram (65 versus 5 percent), and the most common side effects of sarcosine were nausea and sedation. However, problems with the study include the relatively low dose of citalopram, a high rate of attrition, and a remission rate with citalopram that was substantially lower than is typically observed [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins</strong> – Multiple randomized trials indicate that vitamins do not increase the benefits of antidepressants for the initial treatment of unipolar major depression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 52-week trial compared <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (20 to 40 mg/day) plus vitamin B<sub>12</sub> (0.5 mg/day), <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (2 mg/day), and vitamin B<sub>6</sub> (25 mg/day) with citalopram plus placebo in 146 patients [<a href="#rid102">102</a>]. Remission after 12 weeks was nearly identical for vitamins and placebo (78 and 79 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 12-week trial compared <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> (vitamin B1, 300 mg/day) with placebo in 51 inpatients treated with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (20 mg/day) [<a href="#rid103">103</a>]. Although improvement at week 6 was greater with thiamine than placebo, at week 12 improvement was comparable for the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zinc</strong> – Zinc is an essential trace mineral that has been examined in poorly conducted studies of unipolar depression [<a href="#rid53">53</a>]. A meta-analysis of three small randomized trials, lasting 6 to 12 weeks, compared an antidepressant plus zinc (25 mg/day) with an antidepressant plus placebo in 104 patients with unipolar major depression [<a href="#rid59">59</a>]. Improvement was greater in patients who received zinc than placebo, and the clinical benefit was moderate to large. However, attrition was high in each study, and each trial used a completer (per protocol) analysis rather than an intent to treat analysis.</p><p></p><p class="bulletIndent1">Additional information about zinc is discussed separately. (See  <a class="medical medical_review" href="/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Zinc'</a>.)</p><p></p><p class="bulletIndent1">Further information about zinc is reviewed on the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fods.od.nih.gov%2Ffactsheets%2FZinc-HealthProfessional%2F&amp;token=d44UoQj%2FuF2JsYhpIvz054QkBdYs9e9422YGyULJglZdR1kUx38WqYe0jSJe00neorfOZ2wJTnbEJJm6D9mu%2FmyGKOhpDgkW1lP%2FjvBV4Tg%3D&amp;TOPIC_ID=90155" target="_blank">National Institutes of Health: Office of Dietary Supplements</a> website.</p><p></p><p class="headingAnchor" id="H3593027665"><span class="h1">MEDICATIONS THAT CAN HELP IN RELATED CONDITIONS</span><span class="headingEndMark"> — </span>Although the following medications have failed to demonstrate efficacy for unipolar major depression, they can be efficacious for related conditions and thus may play an adjunctive role for depression.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buspirone</strong> – Two randomized trials (n = 119 and 102) compared <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a> with placebo as augmentation in patients who did not respond to initial treatment of major depression with a selective serotonin reuptake inhibitor; response with adjunctive buspirone and placebo were comparable [<a href="#rid104">104,105</a>]. However, given buspirone’s efficacy in generalized anxiety disorder, which is frequently comorbid with depression, it may play an adjunctive role in some patients with major depression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong> – <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> has yielded negative results for unipolar major depression in randomized trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Three trials (total n &gt;900 patients) that compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> monotherapy (≤200 mg per day) with placebo for up to eight weeks found no benefit for lamotrigine [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two trials for treatment-resistant, unipolar major depression (total n = 130), add-on <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> was no more effective than placebo [<a href="#rid107">107,108</a>].</p><p></p><p class="bulletIndent1">Despite these negative data, some clinicians observe benefits from <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> in unipolar depressed patients. Whether this reflects a placebo response or the presence of a small subgroup of responsive patients is unknown. Lamotrigine’s efficacy in bipolar disorder, especially in preventing and possibly treating acute bipolar depression, may be related to the occasional efficacy of lamotrigine in unipolar depressed patients.</p><p></p><p class="headingAnchor" id="H741599860"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H3263322785"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15342.html" rel="external">"Patient education: Depression in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83813.html" rel="external">"Patient education: When you have depression and another health problem (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4868.html" rel="external">"Patient education: Depression in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4866.html" rel="external">"Patient education: Depression treatment options for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4872.html" rel="external">"Patient education: Electroconvulsive therapy (ECT) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H84007251"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Many nonstandard therapies that have been investigated for treating unipolar major depression are typically not used due to limited evidence of their efficacy, safety, and tolerability. In some cases, the treatments lack regulatory approval, are available only through a research protocol, or are conceptualized as complementary and alternative therapies. Nevertheless, for depressive episodes that are resistant to many treatments, investigational and nonstandard approaches may be warranted, instead of pursuing further trials with standard treatments that may be futile. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments that may be beneficial</strong> – Based upon randomized trials, several investigational and nonstandard treatments may be beneficial, including medications such as botulinum toxin, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, cytokine inhibitors, and <a class="drug drug_general" data-topicid="142248" href="/d/drug information/142248.html" rel="external">zuranolone</a>. In addition, complementary and alternative therapies that may be effective include bright light therapy (for nonseasonal depression), omega-3 fatty acids, and the folate derivatives <a class="drug drug_general" data-topicid="10342" href="/d/drug information/10342.html" rel="external">methylfolate</a> and S-adenosyl methionine. (See <a class="local">'Treatments that may be beneficial'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments that do not appear to be beneficial</strong> – Treatments that do not appear to be beneficial include pharmacotherapies such as <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> plus samidorphan, <a class="drug drug_general" data-topicid="9774" href="/d/drug information/9774.html" rel="external">pindolol</a>, and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, as well as complementary and alternative therapies such as folate, magnesium, and sarcosine. (See <a class="local">'Treatments that do not appear to be beneficial'</a> above.)</p><p></p><p class="bulletIndent1">In addition, for patients with treatment-resistant depression, we recommend<strong> not</strong> prescribing cannabis because of its lack of benefit and potential adverse effects and serious harms (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Complementary and alternative treatments'</a> above.)</p><p></p><p class="headingAnchor" id="H628209034"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Paul Ciechanowski, MD, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff also acknowledges Wayne Katon, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.</a></li><li><a class="nounderline abstract_t">Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.</a></li><li><a class="nounderline abstract_t">Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229.</a></li><li><a class="nounderline abstract_t">McAllister-Williams RH, Christmas DMB, Cleare AJ, et al. Multiple-therapy-resistant major depressive disorder: a clinically important concept. Br J Psychiatry 2018; 212:274.</a></li><li><a class="nounderline abstract_t">Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry 2022; 23:424.</a></li><li class="breakAll">National Center for Complementary and Integrative Health. https://nccih.nih.gov/ (Accessed on September 25, 2019).</li><li><a class="nounderline abstract_t">Asher GN, Gerkin J, Gaynes BN. Complementary Therapies for Mental Health Disorders. Med Clin North Am 2017; 101:847.</a></li><li><a class="nounderline abstract_t">Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158:289.</a></li><li><a class="nounderline abstract_t">Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res 2014; 52:1.</a></li><li><a class="nounderline abstract_t">Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 2012; 46:574.</a></li><li><a class="nounderline abstract_t">Magid M, Finzi E, Kruger TH, et al. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry 2015; 48:205.</a></li><li><a class="nounderline abstract_t">Na KS, Lee KJ, Lee JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:79.</a></li><li><a class="nounderline abstract_t">Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29:216.</a></li><li><a class="nounderline abstract_t">Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand 2019; 139:404.</a></li><li><a class="nounderline abstract_t">Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71:1381.</a></li><li><a class="nounderline abstract_t">Miller AH, Pariante CM. Trial failures of anti-inflammatory drugs in depression. Lancet Psychiatry 2020; 7:837.</a></li><li><a class="nounderline abstract_t">Köhler-Forsberg O, Cusin C, Nierenberg AA. Evolving Issues in the Treatment of Depression. JAMA 2019; 321:2401.</a></li><li><a class="nounderline abstract_t">Zazula R, Husain MI, Mohebbi M, et al. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. Aust N Z J Psychiatry 2021; 55:784.</a></li><li><a class="nounderline abstract_t">Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord 2018; 227:219.</a></li><li><a class="nounderline abstract_t">Jaffe RJ, Novakovic V, Peselow ED. Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol 2013; 36:24.</a></li><li><a class="nounderline abstract_t">Furey ML, Zarate CA Jr. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects. J Clin Psychiatry 2013; 74:850.</a></li><li><a class="nounderline abstract_t">Khajavi D, Farokhnia M, Modabbernia A, et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73:1428.</a></li><li><a class="nounderline abstract_t">Köhler O, Gasse C, Petersen L, et al. The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. Am J Psychiatry 2016; 173:807.</a></li><li><a class="nounderline abstract_t">Salagre E, Fernandes BS, Dodd S, et al. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord 2016; 200:235.</a></li><li><a class="nounderline abstract_t">Yatham MS, Yatham KS, Ravindran AV, Sullivan F. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. J Affect Disord 2019; 257:55.</a></li><li><a class="nounderline abstract_t">Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med 2019; 381:903.</a></li><li><a class="nounderline abstract_t">Clayton AH, Lasser R, Parikh SV, et al. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. Am J Psychiatry 2023; 180:676.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li><a class="nounderline abstract_t">Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29:459.</a></li><li><a class="nounderline abstract_t">Ravindran AV, Balneaves LG, Faulkner G, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. Can J Psychiatry 2016; 61:576.</a></li><li class="breakAll">The Management of Major Depressive Disorder Work Group. VA/DoD Clinical Practice Guideline. The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office. Version 4.0 - 2022.</li><li class="breakAll">American Psychiatric Association. WORK GROUP ON MAJOR DEPRESSIVE DISORDER. PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder. Third Edition. 2010. https://psychiatryonline.org/guidelines (Accessed on May 02, 2023).</li><li><a class="nounderline abstract_t">Perera S, Eisen R, Bhatt M, et al. Light therapy for non-seasonal depression: systematic review and meta-analysis. BJPsych Open 2016; 2:116.</a></li><li><a class="nounderline abstract_t">Al-Karawi D, Jubair L. Bright light therapy for nonseasonal depression: Meta-analysis of clinical trials. J Affect Disord 2016; 198:64.</a></li><li><a class="nounderline abstract_t">Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162:656.</a></li><li><a class="nounderline abstract_t">Geoffroy PA, Schroder CM, Reynaud E, Bourgin P. Efficacy of light therapy versus antidepressant drugs, and of the combination versus monotherapy, in major depressive episodes: A systematic review and meta-analysis. Sleep Med Rev 2019; 48:101213.</a></li><li><a class="nounderline abstract_t">Penders TM, Stanciu CN, Schoemann AM, et al. Bright Light Therapy as Augmentation of Pharmacotherapy for Treatment of Depression: A Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord 2016; 18.</a></li><li><a class="nounderline abstract_t">Cunningham JEA, Stamp JA, Shapiro CM. Sleep and major depressive disorder: a review of non-pharmacological chronotherapeutic treatments for unipolar depression. Sleep Med 2019; 61:6.</a></li><li><a class="nounderline abstract_t">Veronese N, Stubbs B, Solmi M, et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med 2018; 80:154.</a></li><li><a class="nounderline abstract_t">Humpston C, Benedetti F, Serfaty M, et al. Chronotherapy for the rapid treatment of depression: A meta-analysis. J Affect Disord 2020; 261:91.</a></li><li><a class="nounderline abstract_t">Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012; 169:937.</a></li><li class="breakAll">Bobo WV, Shelton RC. Treatment of depression. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1151.</li><li><a class="nounderline abstract_t">Roberts E, Carter B, Young AH. Caveat emptor: Folate in unipolar depressive illness, a systematic review and meta-analysis. J Psychopharmacol 2018; 32:377.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. J Clin Psychiatry 2017; 78:703.</a></li><li><a class="nounderline abstract_t">Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev 2016; 10:CD011286.</a></li><li><a class="nounderline abstract_t">Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167:942.</a></li><li><a class="nounderline abstract_t">Mischoulon D, Price LH, Carpenter LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry 2014; 75:370.</a></li><li><a class="nounderline abstract_t">Sharma A, Gerbarg P, Bottiglieri T, et al. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry 2017; 78:e656.</a></li><li><a class="nounderline abstract_t">Cao ZY, Liu YZ, Li JM, et al. Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial. J Affect Disord 2020; 265:247.</a></li><li><a class="nounderline abstract_t">Janakiramaiah N, Gangadhar BN, Naga Venkatesha Murthy PJ, et al. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord 2000; 57:255.</a></li><li><a class="nounderline abstract_t">Sharma A, Barrett MS, Cucchiara AJ, et al. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study. J Clin Psychiatry 2017; 78:e59.</a></li><li><a class="nounderline abstract_t">Aalbers S, Fusar-Poli L, Freeman RE, et al. Music therapy for depression. Cochrane Database Syst Rev 2017; 11:CD004517.</a></li><li><a class="nounderline abstract_t">Firth J, Teasdale SB, Allott K, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019; 18:308.</a></li><li><a class="nounderline abstract_t">Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75:628.</a></li><li><a class="nounderline abstract_t">Guu TW, Mischoulon D, Sarris J, et al. A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. J Affect Disord 2020; 265:233.</a></li><li><a class="nounderline abstract_t">Guu TW, Mischoulon D, Sarris J, et al. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychother Psychosom 2019; 88:263.</a></li><li><a class="nounderline abstract_t">Sarris J, Murphy J, Mischoulon D, et al. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry 2016; 173:575.</a></li><li><a class="nounderline abstract_t">Mocking RJ, Harmsen I, Assies J, et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016; 6:e756.</a></li><li><a class="nounderline abstract_t">Schefft C, Kilarski LL, Bschor T, Köhler S. Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2017; 27:1090.</a></li><li><a class="nounderline abstract_t">Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2016; 209:192.</a></li><li><a class="nounderline abstract_t">Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9:e96905.</a></li><li><a class="nounderline abstract_t">Nikolova VL, Cleare AJ, Young AH, Stone JM. Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Nikolova VL, Cleare AJ, Young AH, Stone JM. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA Psychiatry 2023; 80:842.</a></li><li class="breakAll">American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).</li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li class="breakAll">NICE. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline 222 (ng222). Published June 29, 2022. https://www.nice.org.uk/guidance/ng222 (Accessed on May 05, 2023).</li><li class="breakAll">Taylor DM, Barnes TRE, Young AH. Depression and anxiety disorders. In: The Maudsley Prescribing Guidelines in Psychiatry, Fourteenth Edition, John Wiley &amp; Sons Ltd, West Sussex, UK 2021. p.305.</li><li class="breakAll">VA/DoD Clinical Practice Guideline. The Management of Major Depressive Disorder. 2022. Washington, DC: U.S. Government Printing Office.</li><li><a class="nounderline abstract_t">Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; :CD000448.</a></li><li><a class="nounderline abstract_t">Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatr Dis Treat 2016; 12:1715.</a></li><li><a class="nounderline abstract_t">Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. J Affect Disord 2017; 210:211.</a></li><li class="breakAll">NICE. National Institute for Health and Care Excellence. Implanted vagus nerve stimulation for treatment-resistant depression. Interventional procedures guidance [IPG679]. Published August 12, 2020. https://www.nice.org.uk/guidance/ipg679 (Accessed on May 03, 2023).</li><li><a class="nounderline abstract_t">Hanusch KU, Janssen CH, Billheimer D, et al. Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling. Am J Psychiatry 2013; 170:802.</a></li><li><a class="nounderline abstract_t">Janssen CW, Lowry CA, Mehl MR, et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2016; 73:789.</a></li><li><a class="nounderline abstract_t">Naumann J, Grebe J, Kaifel S, et al. Effects of hyperthermic baths on depression, sleep and heart rate variability in patients with depressive disorder: a randomized clinical pilot trial. BMC Complement Altern Med 2017; 17:172.</a></li><li><a class="nounderline abstract_t">Dinoff A, Lynch ST, Sekhri N, Klepacz L. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. J Affect Disord 2020; 271:91.</a></li><li><a class="nounderline abstract_t">Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013; 16:501.</a></li><li><a class="nounderline abstract_t">Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 2006; 93:239.</a></li><li><a class="nounderline abstract_t">Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry 2015; 172:950.</a></li><li><a class="nounderline abstract_t">McAllister-Williams RH, Anderson IM, Finkelmeyer A, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 2016; 3:117.</a></li><li><a class="nounderline abstract_t">Nagele P, Duma A, Kopec M, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry 2015; 78:10.</a></li><li><a class="nounderline abstract_t">Portella MJ, de Diego-Adeliño J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72:962.</a></li><li><a class="nounderline abstract_t">Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol 2010; 24:513.</a></li><li><a class="nounderline abstract_t">Mathew SJ, Gueorguieva R, Brandt C, et al. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology 2017; 42:2567.</a></li><li><a class="nounderline abstract_t">Bhasin S, Seidman S. Testosterone Treatment of Depressive Disorders in Men: Too Much Smoke, Not Enough High-Quality Evidence. JAMA Psychiatry 2019; 76:9.</a></li><li><a class="nounderline abstract_t">Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009; 15:289.</a></li><li><a class="nounderline abstract_t">Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry 2019; 76:31.</a></li><li><a class="nounderline abstract_t">Dichtel LE, Carpenter LL, Nyer M, et al. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry 2020; 177:965.</a></li><li><a class="nounderline abstract_t">Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6:995.</a></li><li class="breakAll">The National Academies of Science, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017. https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state (Accessed on May 10, 2021).</li><li class="breakAll">Council on Addictions, American Psychiatric Association. Resource Document on Opposition to Cannabis as Medicine. October, 2018. https://www.psychiatry.org (Accessed on May 10, 2021).</li><li><a class="nounderline abstract_t">Tourjman SV, Buck G, Jutras-Aswad D, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Can J Psychiatry 2023; 68:299.</a></li><li><a class="nounderline abstract_t">Nelson JC. The evolving story of folate in depression and the therapeutic potential of l-methylfolate. Am J Psychiatry 2012; 169:1223.</a></li><li><a class="nounderline abstract_t">Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014; 29:55.</a></li><li><a class="nounderline abstract_t">Phelan D, Molero P, Martínez-González MA, Molendijk M. Magnesium and mood disorders: systematic review and meta-analysis. BJPsych Open 2018; 4:167.</a></li><li><a class="nounderline abstract_t">Gao L, Wu C, Liao Y, Wang J. Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial. J Affect Disord 2020; 265:99.</a></li><li><a class="nounderline abstract_t">Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61:343.</a></li><li><a class="nounderline abstract_t">Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine 2015; 22:394.</a></li><li><a class="nounderline abstract_t">Lin JC, Chan MH, Lee MY, et al. N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71:7.</a></li><li><a class="nounderline abstract_t">Huang CC, Wei IH, Huang CL, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 2013; 74:734.</a></li><li><a class="nounderline abstract_t">Mathew SJ. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry 2013; 74:710.</a></li><li><a class="nounderline abstract_t">Almeida OP, Ford AH, Hirani V, et al. B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial. Br J Psychiatry 2014; 205:450.</a></li><li><a class="nounderline abstract_t">Ghaleiha A, Davari H, Jahangard L, et al. Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial. Eur Arch Psychiatry Clin Neurosci 2016; 266:695.</a></li><li><a class="nounderline abstract_t">Landén M, Björling G, Agren H, Fahlén T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59:664.</a></li><li><a class="nounderline abstract_t">Appelberg BG, Syvälahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62:448.</a></li><li><a class="nounderline abstract_t">Amann B, Born C, Crespo JM, et al. Lamotrigine: when and where does it act in affective disorders? A systematic review. J Psychopharmacol 2011; 25:1289.</a></li><li><a class="nounderline abstract_t">Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008; 10:187.</a></li><li><a class="nounderline abstract_t">Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72:1405.</a></li></ol></div><div id="topicVersionRevision">Topic 90155 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074942" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Multiple recurrences of major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517072" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multiple-therapy-resistant major depressive disorder: a clinically important concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35311615" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35311615" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802467" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Complementary Therapies for Mental Health Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156813" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The use of complementary and alternative therapies to treat anxiety and depression in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345483" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22364892" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Facing depression with botulinum toxin: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252721" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24056287" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911574" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834514" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25322082" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949510" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Trial failures of anti-inflammatory drugs in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31125042" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evolving Issues in the Treatment of Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33092404" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102836" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334071" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Scopolamine as an antidepressant: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021505" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146150" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27138586" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27148902" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31299405" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Do statins have an effect on depressive symptoms? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483961" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trial of SAGE-217 in Patients with Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37132201" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25969470" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486153" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486153" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486153" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27703764" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Light therapy for non-seasonal depression: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27011361" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bright light therapy for nonseasonal depression: Meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800134" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600678" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of light therapy versus antidepressant drugs, and of the combination versus monotherapy, in major depressive episodes: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27835725" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bright Light Therapy as Augmentation of Pharmacotherapy for Treatment of Depression: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31262550" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sleep and major depressive disorder: a review of non-pharmacological chronotherapeutic treatments for unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29076953" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606606" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronotherapy for the rapid treatment of depression: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864465" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864465" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29442609" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Caveat emptor: Folate in unipolar depressive illness, a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682531" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27727432" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : S-adenosyl methionine (SAMe) for depression in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595412" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500245" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682528" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090748" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708840" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27898207" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29144545" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Music therapy for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31496103" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004186" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090746" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31480057" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113121" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26978738" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988944" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27103682" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24805797" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33567631" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314797" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314797" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843608" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : St John's wort for major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468236" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064110" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064110" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23820835" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27172277" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28351399" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of hyperthermic baths on depression, sleep and heart rate variability in patients with depressive disorder: a randomized clinical pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479336" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23174090" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677714" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423481" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26727041" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577164" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034693" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832428" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28553836" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30428087" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Testosterone Treatment of Depressive Disorders in Men: Too Much Smoke, Not Enough High-Quality Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625884" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Testosterone and depression: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30427999" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660299" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672337" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672337" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672337" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35711159" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212050" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The evolving story of folate in depression and the therapeutic potential of l-methylfolate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424706" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A meta-analysis of inositol for depression and anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897029" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Magnesium and mood disorders: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090788" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17990195" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25837277" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27296677" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23562005" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144323" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Glycine transporter-I inhibitors: a new class of antidepressant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257064" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26984349" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921700" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11465522" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823080" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lamotrigine: when and where does it act in affective disorders? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18615166" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367355" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
